BIOGEN INC.
BIIBAPI behind this page
BIIB FY 2025 request
Playground key active
/api/financials?ticker=BIIB&year=2025&quarter=4&full_year_mode=true
Pick an endpoint and run the request.Income Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Revenue | 9,890.6 | 9,675.9 | +2.2% |
Show Product Lines breakouts |
|||
| Alzheimer's collaboration revenue | 177.7 | 59.9 | +196.7% |
| AVONEX | 695.5 | 707.5 | -1.7% |
| AVONEX · Non Us | 212.6 | 256.2 | -17.0% |
| AVONEX · US | 482.9 | 451.3 | +7.0% |
| BENEPALI | 453.2 | 479.1 | -5.4% |
| BENEPALI · Non Us | 453.2 | 479.1 | -5.4% |
| BYOOVIZ | 32.4 | 36.6 | -11.5% |
| BYOOVIZ · Non Us | 19.4 | 13.6 | +42.6% |
| BYOOVIZ · US | 13 | 23 | -43.5% |
| Completed technology for SKYCLARYS (U.S.) | 520.5 | 382.5 | +36.1% |
| Completed technology for SKYCLARYS (U.S.) · Non Us | 209.9 | 81.4 | +157.9% |
| Completed technology for SKYCLARYS (U.S.) · US | 310.6 | 301.1 | +3.2% |
| Contract manufacturing revenue | 679.4 | 592.1 | +14.7% |
| Contract manufacturing, royalty and other revenue | 732.9 | 652.6 | +12.3% |
| Contract manufacturing, royalty and other revenue · Reportable Segment | 10.8 | 0.4 | +2600.0% |
| Contract manufacturing, royalty and other revenue · Reportable Segment | 414.7 | 395 | +5.0% |
| Contract manufacturing, royalty and other revenue · Reportable Segment | 307.4 | 257.2 | +19.5% |
| Contract manufacturing, royalty and other revenue · Reportable Segment | 732.9 | 652.6 | +12.3% |
| FAMPYRA(1) | 1.4 | 71.7 | -98.0% |
| FAMPYRA(1) · Non Us | 1.4 | 71.7 | -98.0% |
| FLIXABI | 52.6 | 63.2 | -16.8% |
| FLIXABI · Non Us | 52.6 | 63.2 | -16.8% |
| FUMADERM And ADUHELM | 2.1 | 10.3 | -79.6% |
| FUMADERM And ADUHELM · Non Us | 1.7 | 7.5 | -77.3% |
| FUMADERM And ADUHELM · US | 0.4 | 2.8 | -85.7% |
| IMRALDI | 190.2 | 213.1 | -10.7% |
| IMRALDI · Non Us | 190.2 | 213.1 | -10.7% |
| Other | 197.2 | 82.5 | +139.0% |
| Other · Non Us | 1.7 | 7.5 | -77.3% |
| Other · US | 195.5 | 75 | +160.7% |
| PLEGRIDY | 250.1 | 260.5 | -4.0% |
| PLEGRIDY · Non Us | 145.2 | 149.1 | -2.6% |
| PLEGRIDY · US | 104.9 | 111.4 | -5.8% |
| Product | 7,119.4 | 7,213.5 | -1.3% |
| Product · Non Us | 3,571.5 | 3,976.2 | -10.2% |
| Product · Reportable Segment | 1,871.6 | 2,171.5 | -13.8% |
| Product · Reportable Segment | 427.8 | 482.2 | -11.3% |
| Product · Reportable Segment | 853 | 955.6 | -10.7% |
| Product · Reportable Segment | 3,547.9 | 3,237.3 | +9.6% |
| Product · Reportable Segment | 419.1 | 366.9 | +14.2% |
| Product · Reportable Segment | 7,119.4 | 7,213.5 | -1.3% |
| Product · US | 3,547.9 | 3,237.3 | +9.6% |
| QALSODY | 86.9 | 32.4 | +168.2% |
| QALSODY · Non Us | 56.8 | 11.5 | +393.9% |
| QALSODY · US | 30.1 | 20.9 | +44.0% |
| Revenue from anti-CD20 therapeutic programs | 1,860.6 | 1,749.9 | +6.3% |
| Revenue from anti-CD20 therapeutic programs · Reportable Segment | 1.8 | 0.6 | +200.0% |
| Revenue from anti-CD20 therapeutic programs · Reportable Segment | 83.4 | 75.7 | +10.2% |
| Revenue from anti-CD20 therapeutic programs · Reportable Segment | 1,775.4 | 1,673.6 | +6.1% |
| Revenue from anti-CD20 therapeutic programs · Reportable Segment | 1,860.6 | 1,749.9 | +6.3% |
| Royalty | 53.5 | 60.5 | -11.6% |
| Royalty revenue on sales of OCREVUS | 1,414.9 | 1,339.5 | +5.6% |
| SPINRAZA | 1,546.8 | 1,573.2 | -1.7% |
| SPINRAZA · Non Us | 921.3 | 947.5 | -2.8% |
| SPINRAZA · US | 625.5 | 625.7 | -0.0% |
| Subtotal: Biosimilars | 729.1 | 793.1 | -8.1% |
| Subtotal: Biosimilars · Non Us | 715.4 | 769 | -7.0% |
| Subtotal: Biosimilars · US | 13.7 | 24.1 | -43.2% |
| Subtotal: Multiple Sclerosis | 4,038.9 | 4,349.8 | -7.1% |
| Subtotal: Multiple Sclerosis · Non Us | 1,666.4 | 2,159.3 | -22.8% |
| Subtotal: Multiple Sclerosis · US | 2,372.5 | 2,190.5 | +8.3% |
| Subtotal: Rare Disease | 2,154.2 | 1,988.1 | +8.4% |
| Subtotal: Rare Disease · Non Us | 1,188 | 1,040.4 | +14.2% |
| Subtotal: Rare Disease · US | 966.2 | 947.7 | +2.0% |
| TECFIDERA | 679.7 | 967.1 | -29.7% |
| TECFIDERA · Non Us | 511.2 | 797.9 | -35.9% |
| TECFIDERA · US | 168.5 | 169.2 | -0.4% |
| TOFIDENCE | 0.7 | 1.1 | -36.4% |
| TOFIDENCE · US | 0.7 | 1.1 | -36.4% |
| Total Fumarate | 1,426.5 | 1,595.1 | -10.6% |
| Total Fumarate · Non Us | 606.8 | 887.3 | -31.6% |
| Total Fumarate · US | 819.7 | 707.8 | +15.8% |
| Total Interferon | 945.6 | 968 | -2.3% |
| Total Interferon · Non Us | 357.8 | 405.3 | -11.7% |
| Total Interferon · US | 587.8 | 562.7 | +4.5% |
| TYSABRI | 1,665.4 | 1,715 | -2.9% |
| TYSABRI · Non Us | 700.4 | 795 | -11.9% |
| TYSABRI · US | 965 | 920 | +4.9% |
| VUMERITY | 746.8 | 628 | +18.9% |
| VUMERITY · Non Us | 95.6 | 89.4 | +6.9% |
| VUMERITY · US | 651.2 | 538.6 | +20.9% |
| ZURZUVAE | 195.1 | 72.2 | +170.2% |
| ZURZUVAE · US | 195.1 | 72.2 | +170.2% |
Show Business Segments breakouts |
|||
| Reportable Segment | 9,890.6 | 9,675.9 | +2.2% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -72.4 | 18.1 | -500.0% |
Show Type Of Arrangement breakouts |
|||
| Samsung Bioepis | 15.5 | 14.4 | +7.6% |
| Cost of Revenue | 2,404.2 | 2,310.4 | +4.1% |
Show Product Lines breakouts |
|||
| Clinical Inventory · Reata Pharmaceuticals, Inc | 23.9 | 48.5 | -50.7% |
| Product · Reportable Segment | 1,587.2 | 1,604.2 | -1.1% |
| Royalty · Reportable Segment | 817 | 706.2 | +15.7% |
| SPINRAZA · Ionis Pharmaceuticals | 212.3 | 216.1 | -1.8% |
| Research And Development Expense Excluding Acquired In Process Cost | 1,778.6 | 1,980.3 | -10.2% |
Show Business Segments breakouts |
|||
| Reportable Segment · Early stage programs | 257.7 | 286.6 | -10.1% |
| Reportable Segment · Late stage programs | 232 | 209.7 | +10.6% |
| Reportable Segment · Marketed products | 412.8 | 534.7 | -22.8% |
| Reportable Segment · Research and discovery | 183.2 | 201.5 | -9.1% |
| Reportable Segment · Service Other | 692.9 | 747.8 | -7.3% |
Show Type Of Arrangement breakouts |
|||
| Ionis Pharmaceuticals | 7.5 | 7.5 | 0.0% |
| Other research and discovery | 13.4 | 54 | -75.2% |
| Research And Development Expense Acquired In Process Cost | 471.8 | 61.5 | +667.2% |
| Selling, General & Administrative | 2,433.6 | 2,403.7 | +1.2% |
Show Business Segments breakouts |
|||
| Reportable Segment | 2,433.6 | 2,403.7 | +1.2% |
| Amortization And Impairment Of Acquired Intangible Assets | 515 | 446.7 | +15.3% |
| Collaboration Profit Loss Sharing | 290.2 | 254.4 | +14.1% |
Show Type Of Arrangement breakouts |
|||
| Samsung Bioepis | 219.2 | 227.4 | -3.6% |
| Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Gain Loss Included In Earnings | 33.6 | 27.7 | +21.3% |
| Operating Lease Impairment Loss | 52.9 | — | — |
| Restructuring Charges | 48.6 | 30.2 | +60.9% |
Show Income Statement Location breakouts |
|||
| Research And Development Expense · 2023 Cost Saving Initiatives | 10.1 | 11.7 | -13.7% |
| Research And Development Expense · Reata Integration | 14.3 | 11.9 | +20.2% |
| Restructuring Charges · 2023 Cost Saving Initiatives | 48.7 | 24.2 | +101.2% |
| Restructuring Charges · Reata Integration | -0.7 | 3.4 | -120.6% |
| Selling General And Administrative Expenses · 2023 Cost Saving Initiatives | -1.4 | 13.8 | -110.1% |
| Selling General And Administrative Expenses · Reata Integration | 6.8 | 6.3 | +7.9% |
Show Restructuring Cost And Reserve breakouts |
|||
| Workforce Reduction | 48.6 | 30.2 | +60.9% |
Show Restructuring Plan breakouts |
|||
| 2023 Cost Saving Initiatives | 57.4 | 49.7 | +15.5% |
| Reata Integration | 20.4 | 21.6 | -5.6% |
| Non-Operating Income (Expense) | 305.6 | 343.6 | -11.1% |
| Total Costs & Expenses | 8,334.1 | 7,769.9 | +7.3% |
| Income Before Taxes | 1,556.5 | 1,906 | -18.3% |
| Income Tax Expense (Benefit) | 263.6 | 273.8 | -3.7% |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | 5.5 | -0.6 | +1016.7% |
| Net Income | 1,292.9 | 1,632.2 | -20.8% |
Show Equity Components breakouts |
|||
| Retained Earnings | 1,292.9 | 1,632.2 | -20.8% |
Show Business Acquisition breakouts |
|||
| Reata Pharmaceuticals, Inc · Fair Value Adjustment To Inventory | 240.8 | 230 | +4.7% |
| Net Income | 1,292.9 | 1,632.2 | -20.8% |
Show Business Segments breakouts |
|||
| Reportable Segment | 1,292.9 | 1,632.2 | -20.8% |
Show Reclassification Out Of Accumulated Other Comprehensive Income breakouts |
|||
| Reclassification Out Of Accumulated Other Comprehensive Income | -45.9 | 4.2 | -1192.9% |
| EPS (Basic) | 8.83 | 11.21 | -21.2% |
| EPS (Diluted) | 8.79 | 11.18 | -21.4% |
| Wtd Avg Shares (Basic) | 146.5 | 145.6 | +0.6% |
| Wtd Avg Shares (Diluted) | 147.1 | 145.9 | +0.8% |
| Operating Expenses (FY) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Gain Loss Net Cash Flow Hedge Parent · Reclassification Out Of Accumulated Other Comprehensive Income | -21.3 | 12.9 | -265.1% |
| Interest Income | -125 | -67.6 | -84.9% |
| Other Non-Operating Income (Expense) | -24.7 | 3.3 | -848.5% |
| Comprehensive Income | 1,247.1 | 1,649.7 | -24.4% |
| Other Comprehensive Income | -45.8 | 17.5 | -361.7% |
Show Equity Components breakouts |
|||
| Accumulated Net Unrealized Investment Gain Loss | 0.2 | — | — |
| Foreign Currency Transaction Gain Loss Before Tax | 28.6 | 30.9 | -7.4% |
| Interest Expense | 267.5 | 250.3 | +6.9% |
Balance Sheet
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 3,008.5 | 2,375 | +26.7% |
| Available For Sale Securities Debt Securities Current | 807.2 | — | — |
| Accounts Receivable | 1,342.4 | 1,404.8 | -4.4% |
| Due From Unconsolidated Joint Business | 524.6 | 464 | +13.1% |
| Inventory | 2,168.1 | 2,460.5 | -11.9% |
| Other Assets Current | 1,123.3 | 752.5 | +49.3% |
| Total Current Assets | 8,974.1 | 7,456.8 | +20.3% |
| Non-Current Assets | |||
| Available For Sale Securities Debt Securities Noncurrent | 431.9 | — | — |
| Property, Plant & Equipment | 3,055.4 | 3,181.3 | -4.0% |
| Operating Lease Right-of-Use Assets | 265.4 | 356.4 | -25.5% |
| Goodwill | 6,491.1 | 6,478.9 | +0.2% |
Show Business Acquisition breakouts |
|||
| Reata Pharmaceuticals, Inc | 469.2 | — | — |
| Deferred Tax Assets | 292.5 | 324.2 | -9.8% |
| Other Non-Current Assets | 750.6 | 560.5 | +33.9% |
| Total Assets | 29,439.5 | 28,049.3 | +5.0% |
| Intangible Assets | 7,379.5 | 7,884.3 | -6.4% |
| Other Assets | |||
| Intangible Assets Net Excluding Goodwill | 9,178.5 | 9,691.2 | -5.3% |
| Current Liabilities | |||
| Taxes Payable Current | 114.8 | 548.3 | -79.1% |
| Accounts Payable | 432 | 424.2 | +1.8% |
| Other Liabilities Current | 2,802.6 | 2,807.7 | -0.2% |
| Total Current Liabilities | 3,349.4 | 5,528.8 | -39.4% |
| Non-Current Liabilities | |||
| Deferred Tax Liabilities | 507.6 | 190.5 | +166.5% |
| Operating Lease Liabilities | 290.4 | 334.5 | -13.2% |
| Other Non-Current Liabilities | 748.5 | 732.3 | +2.2% |
| Total Liabilities | 11,182.7 | 11,333.3 | -1.3% |
| Long-Term Debt | 6,286.8 | — | — |
| Accrued Income Taxes Noncurrent | 166.4 | 156.7 | +6.2% |
| Other Liabilities | |||
| Long Term Notes Payable | 6,286.8 | 4,547.2 | +38.3% |
Show Debt Instrument breakouts |
|||
| 2.250% Senior Notes due May 1, 2030 · Senior Notes | 1,495.7 | 1,494.7 | +0.1% |
| 3.150% Senior Notes due May 1, 2050 · Senior Notes | 1,475.6 | 1,475 | 0.0% |
| 3.250% Senior Notes due February 15, 2051 · Senior Notes | 480.3 | 476.4 | +0.8% |
| 5.050% Senior Notes due January 15, 2031 · Senior Notes | 398 | — | — |
| 5.200% Senior Notes due September 15, 2045 · Senior Notes | 1,101.5 | 1,101.1 | 0.0% |
| 5.750% Senior Notes due May 15, 2035 · Senior Notes | 645.5 | — | — |
| 6.450% Senior Notes due May 15, 2055 · Senior Notes | 690.2 | — | — |
Show Long-Term Debt Type breakouts |
|||
| Senior Notes | 6,286.8 | 4,547.2 | +38.3% |
| Stockholders' Equity | |||
| Common Stock Value Outstanding | 0.1 | 0.1 | 0.0% |
| Additional Paid-In Capital | 863.1 | 569.4 | +51.6% |
| Accumulated Other Comprehensive Income | -182 | -136.2 | -33.6% |
| Retained Earnings | 20,552.7 | 19,259.8 | +6.7% |
| Treasury Stock Value | -2,977.1 | -2,977.1 | 0.0% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 18,256.8 | 16,716 | +9.2% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -182 | -136.2 | -33.6% |
| Additional Paid In Capital | 863.1 | 569.4 | +51.6% |
| Common Stock | 0.1 | 0.1 | 0.0% |
| Retained Earnings | 20,552.7 | 19,259.8 | +6.7% |
| Treasury Stock Common | -2,977.1 | -2,977.1 | 0.0% |
| Total Liabilities & Equity | 29,439.5 | 28,049.3 | +5.0% |
| Total Stockholders' Equity (Q) | — | — | — |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -9.4 | -16.6 | +43.4% |
| Accumulated Gain Loss Net Cash Flow Hedge Parent | -58.9 | 51.6 | -214.1% |
| Accumulated Net Unrealized Investment Gain Loss | 0.2 | — | — |
| Accumulated Other Comprehensive Income | -182 | -136.2 | -33.6% |
| Accumulated Translation Adjustment | -113.9 | -171.2 | +33.5% |
Cash Flow Statement
| Metric | FY 2025 | FY 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 779.9 | 673.2 | +15.8% |
| Impairment Of Intangible Assets Excluding Goodwill | 7.9 | 60.2 | -86.9% |
Show Type Of Arrangement breakouts |
|||
| Samsung Bioepis | 20.2 | — | — |
| Inventory Write Down | 29.2 | 101.9 | -71.3% |
| Amortization Of Inventory Step Up | 240.8 | 230 | +4.7% |
| Research And Development Asset Acquired Other Than Through Business Combination Written Off | 85 | — | — |
| Stock-Based Compensation | 290.8 | 291.2 | -0.1% |
| Deferred Income Taxes | 361.6 | -158.1 | +328.7% |
| Increase Decrease In Equity Securities Fv Ni | 19.3 | 101.4 | -81.0% |
| Other Non-Cash Items | 68.3 | 159.6 | -57.2% |
| Change in Accounts Receivable | 102.7 | 222.3 | -53.8% |
| Increase Decrease In Other Operating Capital Net | -60.6 | -28.1 | -115.7% |
| Change in Inventory | -64.7 | -273.8 | +76.4% |
| Increase Decrease In Accrued Liabilities | 171.1 | 24.6 | +595.5% |
| Increase Decrease In Accrued Income Taxes Payable | -958.1 | 78.5 | -1320.5% |
| Increase Decrease In Other Operating Liabilities | -248 | -178.7 | -38.8% |
| Net Cash from Operations | 2,204.6 | 2,875.5 | -23.3% |
| Investing Activities | |||
| Capital Expenditures | -153.8 | -153.7 | -0.1% |
| Proceeds From Sale And Maturity Of Available For Sale Securities | 23 | — | — |
| Purchases of Investments | -1,258.3 | — | — |
| Payments To Acquire In Process Research And Development | -50 | — | — |
Show Asset Acquisition breakouts |
|||
| Alcyone Therapeutics, Inc. | -85 | — | — |
| Payments To Acquire Intangible Assets | -31.6 | -206.1 | +84.7% |
| Proceeds From Sale Of Equity Method Investments | 56.7 | 144.7 | -60.8% |
| Other Investing Activities | 42.9 | -4.7 | +1012.8% |
| Net Cash from Investing | -1,371.1 | -799.2 | -71.6% |
| Financing Activities | |||
| Tax Withholding for Share Compensation | -10 | -31.3 | +68.1% |
| Proceeds From Issuance Of Long Term Debt | 1,733.1 | — | — |
| Repayments Of Long Term Debt | -1,750 | -650 | -169.2% |
| Payment For Contingent Consideration Liability Financing Activities | -280 | — | — |
| Proceeds From Payments For Other Financing Activities | 5 | -2.2 | +327.3% |
| Net Cash from Financing | -301.9 | -683.5 | +55.8% |
| Supplemental | |||
| Income Taxes Paid | 864 | 355.1 | +143.3% |
| Interest Paid | 264.1 | 245.4 | +7.6% |
| Other Cash Flow | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | 531.6 | 1,392.8 | -61.8% |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 101.9 | -67.7 | +250.5% |
Values in millions USD. Source: SEC EDGAR 10-K filing.